Chroneme interprets the trajectory before there is a reason to look. Every signal, from every provider, across years. No black box, by design. Intelligence clinicians can question, understand, and trust.
We tested Chroneme on data from 208 hospitals, across 49,850 ICU stays. It detected deterioration more than 35 hours before standard scoring systems flagged anything. When the same engine moved to an independent database, 99.4% of performance was retained.
Zohaib Akhtar is the founder of Chroneme. His cross-disciplinary background spans medicine, public health, biomedical design, business, and AI systems. Also founder of OpenCura. 13 patent families filed.
Chenyu Li, Co-Founder. Adam Wolfe, Co-Founder.
Founded 2025. Chroneme, Inc. 13 patent families filed. Contact: mail@chroneme.com
An AUROC of 0.95 sounds excellent. But if the condition has 5% prevalence, the positive predictive value may be as low as 31%. Most validation studies are conducted at the institution that built the model. Chroneme was validated across 208 hospitals using eICU-CRD and MIMIC-IV, two independent databases with different patient populations.